In a report issued on March 8, Liisa Bayko from JMP Securities reiterated a Buy rating on Achillion Pharmaceuticals (ACHN), with a price target of $6. The company’s shares closed on Friday at $2.69.
According to TipRanks.com, Bayko is a 5-star analyst with an average return of 15.2% and a 47.0% success rate. Bayko covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Enanta Pharmaceuticals, and Sarepta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Achillion Pharmaceuticals with a $6 average price target.
See today’s analyst top recommended stocks >>
Based on Achillion Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $16.6 million. In comparison, last year the company had a GAAP net loss of $23.2 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.
